8-K filing — CalciMedica, Inc. (CALC)
Filed: 2026-09-02 AccNo: 0001193125-26-379419 Size: 140 KB Item 8.01: Other Events
Stocks · News reference
FDA Raises No Concerns Over Auxora Safety Data, CalciMedica Advances Trial
FDA raises no objections to CalciMedica revised Phase 2 KOURAGE trial, allowing Auxora dosing to resume for acute kidney injury.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CalciMedica shares are trading lower after the company announced a 1-for-5 reverse stock split.
CalciMedica Announces 1-For-5 Reverse Stock Split, Effective August 28
CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for
Guggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9
Guggenheim analyst Vamil Divan initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces Price Target of $9.